When should I take Cyclogest IVF?

When should I take Cyclogest IVF?

Cyclogest pessaries is used to treat premenstrual syndrome, postpartum depression, and to support women in assisted reproductive technologies like IVF.

Progesterone, the active component of Cyclogest pessaries, is essential for the reproductive system to function properly.

Additionally administered progesterone is utilized for proper endometrium transformation in the luteal period in order to maximize effective embryo transfer following IVF treatment in Istanbul, Turkey . Progesterone injected vaginally causes the endometrium to secrete enough hormones. (1)

What is Cyclogest?

Progesterone, a naturally occurring female sex hormone generated by the body, is a component of Cyclogest. To treat certain conditions, Cyclogest improves the body’s hormonal balance.

Premenstrual syndrome, which often affects women seven to ten days before their period, is managed with cyclogest. Anxiety, irritability, depression, headaches, breast soreness, weight gain, and bloating are all symptoms of premenstrual syndrome.

Cyclogest aids in preventing postpartum depression, which some women experience following the birth of their child. It is also advised for female patients in assisted reproductive technology (ART) programs who require more progesterone. (2)

How should I use Cyclogest?

Use this medication exactly as directed by your doctor at all times. You should get in touch with your doctor or pharmacist if you are unsure. 

For female participants in the program for ART:

  • A vaginal insertion of 400 mg twice daily is advised. Start taking 400 mg of Cyclogest the day before egg retrieval. Cyclogest should be administered for a further 38 days if pregnancy is found to have occurred.

For premenstrual syndrome and postpartum depression treatment:

  • A rectal or vaginal insertion of 200 mg once daily or 400 mg twice daily is advised.
  • Depending on some of the other circumstances listed below, the pessary may be put into the rectum (back passage) or vagina.

When should I not use Cyclogest?

In the following circumstances, we advise against using Cyclogest and recommend you to discontinue doing so.

  • if you have progesterone or any other medication component allergy 
  • If your doctor has not evaluated your unusual vaginal bleeding 
  • If you have a hormone-sensitive tumor, whether it is recognized or not 
  • If porphyria problems are present (an inherited or acquired group disorder of certain enzymes),
  • If you currently have or ever had blood clots in your legs, lungs, eyes, or any other portion of your body,  
  • If you have severe liver issues now or in the past, 
  • If you’ve had a miscarriage and your doctor thinks there may be some tissue there, or that you are carrying a baby outside the womb. (4)

How should Cyclogest be used during pregnancy and breastfeeding?

Women who require extra progesterone while receiving therapy in an ART program can utilize Cyclogest throughout the first trimester of pregnancy. 

Exogenous progesterone exposure during pregnancy carries a potential risk of congenital anomalies (disorders present at birth), including genital deformities in male or female newborns. 

If you have any other uses for this medication or if you are pregnant, suspect you may be pregnant or are planning a pregnancy, talk to your doctor or pharmacist before using it. When breastfeeding, this medication should not be taken. 

On the 12th or 14th day of your menstrual cycle, start taking Cyclogest for premenstrual tension. Day 1 is the start day of your period and counts up to day 12 or day 14, depending on what your doctor advises. It should be planned and noted on your calendar. (5)


1-Saunders, H., Khan, C., D’Hooghe, T., Magnúsdóttir, T. B., Klingmann, I., Hrafnsdóttir, S., & vaginal progesterone luteal phase support post IVF study group. (2020). Efficacy, safety and tolerability of progesterone vaginal pessaries versus progesterone vaginal gel for luteal phase support after in vitro fertilisation: A randomised controlled trial. Human Reproduction, 35(2), 355-363.

2,3,4,5- https://www.medicines.org.uk/emc/product/5569/pil#gref

Leave a Reply

Your email address will not be published. Required fields are marked *